The leaders in pharmaceutical innovation have been truly love-hate recently. Innovent and WuXi AppTec keep getting positive news, and foreign investors are buying enthusiastically, but the price action shows no real improvement... BeiGene, on the other hand, gave some face with a slight rise, and many are probably just passively waiting for the options expiry. CanSino and RemeGen have wild swings—some get caught up in the frenzy and end up spinning in circles, while the bullish breakout I’ve been waiting for still hasn’t come. Honestly, whether you buy or not now comes with a built-in exhaustion buff. Is it worth it long-term? Still agonizing over it.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
